Participated · Seed · Jul 2022

Impart Security offers an Application Detection and Response Engineering Platform that uses AI agents and programmable WebAssembly (WASM) isolation to design, test, and deploy security rules safely in production. The platform runs coordinated AI agents (Traffic Inspector, Detection Engineer, Security Architect, Rule Engineer) to inspect traffic, spot anomalies, develop and test rules, and adapt defenses in real time. Early deployments have generated over 2,400 security rules, cut average deployment time from 18 days to 45 minutes, and maintained 99.97% uptime while preventing dozens of attack patterns in customer environments. Impart says its WASM-based sandboxes provide secure isolation and high performance, enabling autonomous production changes that customers trust. The company serves major enterprises, including a large financial services firm and a global entertainment conglomerate, and is led by security veterans from major technology companies. Following its Series A, Impart plans to expand into financial services, healthcare, and infrastructure providers and to launch partnerships with major cloud platforms and channel partners. Impart Security builds API security tools that detect threats and vulnerabilities across any API tech stack and resolve them automatically without human intervention. The platform emphasizes monitoring and observability and offers out-of-the-box remediation to avoid noisy alerts that overwhelm security teams. The company was founded by several former Signal Sciences colleagues and is led by CEO and cofounder Jonathan DiVincenzo. Signal Sciences was sold to Fastly for $775 million in 2020, and Impart's team leverages that prior experience in web application and API security. Impart is currently in closed beta with select commerce and enterprise customers and, based on beta feedback, plans a commercial launch in the fourth quarter of 2022. The company announced a $6 million seed round led by CRV with participation from Haystack, 8-bit Capital and O'Reilly AlphaTech Ventures.

Participated · Series B · May 2022

Pachama develops technology that harnesses satellite data and AI to deliver insights on how forests sequester carbon, protect wildlife, and support local livelihoods. The company provides tools that help companies identify and invest in high-quality reforestation and conservation projects and helps land stewards estimate carbon, start projects, and secure funding. Pachama has evaluated projects worldwide and developed Pachama Original projects in Brazil, Mexico, and the United States, and has served clients such as Salesforce, Nespresso, Shopify, and Boston Consulting Group. In Q3 2023 the company reported 57% year‑over‑year growth in credits retired, underscoring increased demand for its rigorously vetted projects. The additional capital announced in the extension will fund R&D in AI applied to geospatial data and expand products and services for companies and project developers. Pachama also announced board appointment of Ebony Beckwith as an independent board member as it scales its nature-based climate solutions. Pachama is a San Francisco-based technology company that leverages satellite imagery, remote sensing and machine learning to measure the carbon stored in forests and monitor forest growth over time. Through its platform, responsible companies can confidently invest in high-quality forest conservation projects verified by Pachama’s evaluation process. The company says it has worked with 46 forest project developers in 14 countries, reviewed over 150 forest projects globally and counts more than 800 sustainably-minded organizations as customers, including Salesforce, Microsoft, Nespresso, Airbnb, Netflix, Softbank, Vuori, and Flexport. Pachama intends to use the Series B proceeds to continue building a scientifically rigorous, technology-based approach to forest carbon credit verification, acquire talent, expand efforts to reach corporate and forest developers, accelerate R&D, and scale the technology needed to transform carbon markets. Diego Saez Gil is CEO and co-founder and the company is based in San Francisco, CA. The new round brings Pachama’s total investment secured to $79M. Pachama operates a verified marketplace for forest carbon credits that combines satellite imagery and machine learning to improve transparency and verifiability. The company says its technology enables validation, monitoring and measurement of forest projects to support corporate carbon-offset purchases. Pachama launched in 2020 and has attracted paying customers including Mercado Libre, Microsoft, Shopify and SoftBank, and received a public shout-out from Jeff Bezos. The startup has recruited talent from companies such as Google, Facebook, SpaceX, Tesla, OpenAI, Microsoft, Impossible Foods and Orbital Insights. Pachama plans to use new funding for product development and continued expansion of its marketplace. Financially, the company raised $15 million in its latest financing and has amassed nearly $24 million in capital since its 2020 launch. Pachama provides remote verification and monitoring of forestry offset projects using satellite imagery and AI to measure carbon captured by forests. The company offers enterprise tools to onboard and monitor carbon removal projects, creating new levels of measurement, monitoring, and verification. Pachama said it will scale its forest restoration and conservation emissions‑reduction monitoring service. To support that effort it raised $5 million in fresh funding, bringing total capital raised to $9 million. The product is positioned as timely amid Western US wildfires and ongoing deforestation globally. Founder Diego Saez‑Gil lost his home in the California wildfires earlier this year, and investors cited growing corporate demand from businesses with ESG commitments. Pachama builds a marketplace to connect verified reforestation projects with buyers of carbon offsets and provides monitoring and management services using satellite imagery and sensors. The company verifies projects approved by existing certification bodies and seeks to bring trust and independent validation to carbon markets. Founder Diego Saez-Gil launched the effort after observing deforestation impacts firsthand and the company currently lists 23 forest projects in Brazil, Peru and multiple U.S. states (California, Vermont, New Jersey, Connecticut and Maine). Pachama raised $4.1 million from a consortium of investors to create the marketplace and its monitoring software. Its business becomes profitable only if carbon prices exceed about $15 per ton; today only California and European markets have reached that level. The team sees regulatory demand (for example CORSIA for airlines) as a potential driver of future offset demand and plans to scale listings and verification to meet that demand.

Participated · Seed · Nov 2021

Videra Health is an Orem, UT–based company offering an AI-driven mental health assessment platform. Its FDA-registered digital platform uses linguistic, audio and video analysis to help providers proactively identify, triage, and monitor at-risk patients. The company connects providers and patients anytime, anywhere via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform is designed to streamline diagnoses, enhance care accessibility, optimize workflows and reduce costs for providers and healthcare systems. Videra is led by CEO Loren Larsen. It raised $5.6M in a Seed II round and intends to use the funds to expand operations and its reach. Videra Health is an FDA-registered remote patient monitoring video platform that enables asynchronous check-ins and video assessments to capture quantitative and qualitative patient data for behavioral health providers. The platform extracts, organizes and analyzes patient responses to assist clinical decision making and to surface the right patients at the right time. Videra hosts thousands of patient engagements every month for behavioral health providers nationwide and customers report saving approximately 88% of staff time. The company says 91% of providers view remote patient monitoring and post-discharge surveys as essential and 86% of patients want more engagement between appointments, framing the market opportunity. Leadership (founder and CEO Loren Larsen) and investors see AI playing an increasing role in scaling insights and engagement as Videra seeks to expand its impact across patient-centered care paradigms. Videra is based in Orem, Utah and plans to use the new funding to scale patient interactions for behavioral health.

Participated · Seed · Oct 2021

Heart to Heart is an audio-first dating app that uses voice snippets to create more intimate, intentional connections compared with swiping and text-based messaging. The product emphasizes voice, storytelling and confirmed photos as mechanics to slow users down and encourage more thoughtful interaction. The founding team includes CEO Joshua Ogundu alongside engineer Arihant Jain and designer Komal Shrivastava. The company raised $750,000 in a pre-seed round to fund development. Proceeds will be used to build an iOS app and to make Los Angeles the startup's first launch market. The team hopes to get the product to market by the end of the year.

Participated · Seed · Aug 2021

Known Medicine’s ODIN (Oncology Diagnostics Inference Network) platform uses proprietary M3DUSA 3D organoid models and a bespoke IRIS image-analysis pipeline to predict how a patient’s tumor will respond to specific treatments. The M3DUSA model is formulated with automation-friendly hydrogel components and includes cancer, stromal, and immune cells to better recreate the tumor microenvironment. The company combines high-content images with machine learning and high-dimensional -omics datasets to identify which cells respond to treatments and potential resistance mechanisms. Known Medicine is building a purpose-built 3D cell culture dataset that the company says grows by thousands of images with each patient sample. Data can be provided to oncologists as a decision-support tool or supplied via partnerships with biopharmaceutical companies for clinical trial or companion-diagnostic patient selection. Leadership includes co-founders Andrea Mazzocchi, Ph.D. (CEO) and Katie-Rose Skelly (CTO).